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1. Introduction 
In mammalian heart, the sino-atrial (SA) node is the pacemaker region, which contains a 
family of ionic currents that contributes to the pacemaker potential. Using SA nodal cells, 
experiments have shown that dysrhythmias are easily elicited under conditions involving 
calcium overload that occur during ischemia and cardiac failure. Clinically these SA nodal 
dysfunctions cause bradyarrhythmias in general and are associated with syncope but rarely 
with death. To initiate pacemaker function an inward current (If) carried by sodium through 
a family of channels that are hyperpolarization-activated and cyclic nucleotide-gated (HCN 
channels) (Biel et al 2002). 
Recent advances in molecular and cellular biology, specifically in the areas of stem cell 
biology and tissue engineering have initiated the development of a new field in molecular 
biology, regenerative medicine, seeks to develop new biological solutions, using the 
mobilization of endogenous stem cells or delivery of exogenous cells to replace or modify 
the function of diseased, absent, or malfunctioning tissue. As far as adult cardiomyocytes 
have limited regenerative capacity it represents an attractive candidate for these emerging 
technologies. Therefore, dysfunction of the specialized electrical conduction system may 
result in inefficient rhythm initiation or impulse conduction leading to significant 
bradycardia that may require the implantation of a permanent electronic pacemaker. 
Replacement of the dysfunctional myocardium by implantation of external heart muscle 
cells is emerging as a novel paradigm for restoration of the myocardial electromechanical 
properties, but has been significantly limited by the paucity of cell sources for human heart 
cells and by the relatively limited evidence for functional integration between grafted and 
host cells. Human embryonic stem cell lines may provide a possible solution for the cell 
sourcing problem. 
Although electronic pacing is an excellent therapy, still have disadvantage like the need for 
monitoring and replacement, indwelling catheter-electrodes in the heart, possibility of 
infection, and lack of autonomic responsiveness, geometric limitations with respect to 
pediatric patients make it warrant a search for better alternatives (Rosen et al 2004). The 
biological pacemaker, a tissue that spontaneously or via engineering confers pacemaker 
properties to regions of the heart, is an exciting alternative. Several approaches have been 
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taken in attempting to produce biological pacemakers. These can be considered in 3 
headings: 1- The use of viral vectors to deliver genes to regions of the heart such that a 
pacemaker potential resulting in spontaneous impulse initiation evolves in the region of 
gene administration. 2- The use of embryonic stem cells grown along a cardiac lineage and 
manifesting the electrophysiologic properties of sinus node cells; 3- The use of mesenchymal 
stem cells as platforms to carry pacemaker genes to the heart, relying on gap junctional 
coupling such that the stem cell and a coupled myocyte form a single functional unit to 
generate pacemaker function (Edelberg1998, 2001, Miake et al 2002, Qu et al 2003, 
Plotnikovet al 2004, Kehat et al 2004, Potapova et al 2004). 
2. Historical background 
Till the mid-20th century, many patients with complete heart block were at risk of death. 
Therapy in adults was largely limited to positive chronotropic interventions, typically 
sublingual isoproterenol, the first mass-produced implantable pacemakers were fixed rate 
units featuring the attractiveness and dimensions of a sterile hockey puck, but they are life 
saving. Improvements in design and manufacture, insightful adaptation of computer 
technologies to provide programming and microcircuitry, and  the imaginative approaches 
to a variety of cardiac pathologies have ultimately developed pacing used epicardially or 
endocardially to treat disorders of heart rate and rhythm and heart failure. The development 
of cardioverters/defibrillators and their incorporation in the pacemaker industry represent a 
further major development. The hardware and the methods initially applied to a very 
limited spectrum of heart rhythm disorders had grown into the medical device industry and 
into one of the most successful and effective palliative therapies in last 3 decades. 
(Michaelsson et al 1995, Zivin et al 2001a & b). 
3. Anatomical and histological bases 
The SA node region is located on the endocardial surface at the edge of the right atrium, 
bounded on two sides by the superior and inferior venae cavae and around the crista 
terminalis between the venae cavae and the right atrial muscle. Microscopically, the SA 
node appears as a translucent muscular region near the sino-atrial node artery. With most 
prominent feature is the ring bundle, which is a thin flap of tissue that extends around most 
of the periphery of the node and that usually appears to be the most vigorously beating part 
in an isolated node. On electron microscope, SA nodal cells have a relatively large nucleus 
and a few myofilaments. There are many caveolar invaginations along the surface 
membranes of these cells. The intercellular space at 20 nm is wide compared with other 
tissues. Isolated SA nodal cells are spindle- or spider-shaped and have a maximum length of 
25–30µm, with an irregular profile in cross section and a diameter of less than 8µm. Isolated 
spontaneously beating SA nodal myocytes are curved and not flat on their base (Masson-
Pevet  1979,Satoh Uchida 1993, Shinagawa et al 2000). 
4. Physiology of natural pacing 
The sinus node depolarizes spontaneously during phase 4 until membrane potential reaches 
threshold and an action potential is generated. (Phase 4 is initiated at the end of 
repolarization, when the membrane potential is very negative (about -60 mV), ion channels 
open that conduct slow, inward (depolarizing) Na+ currents. These currents are called 
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"funny" currents and abbreviated as "If". These depolarizing currents cause the membrane 
potential to begin spontaneous depolarization). This event occurs rhythmically and 
regularly for the lifetime. The slope of phase 4 depolarization results from a balance 
between inward and outward ion currents. The initial inward current, activated on 
hyperpolarization of the membrane at the end of repolarization, other currents that are 
inward and contribute to phase 4 depolarization are the T- and L-type Ca currents (upstroke 
of the sinus node action potential). Providing outward current during the same time frame 
are the not yet completely decayed potassium currents IKr and IKs and a weak IK1. In 
addition, the Na–Ca exchanger operates during phase 4 to further influence the rate of 
depolarization of the membrane (DiFrancesco 1981, Biel et al 2002, Bogdanov et al 2006). 
The autonomic nervous system modulating the ion channel contribution to pacemaker 
function. Catecholamine binding to beta adrenergic receptors operates via a Gs protein– 
linked pathway to increase cyclic adenosine monophosphate (cAMP) synthesis and increase 
pacemaker rate, whereas acetylcholine binding to M2 muscarinic receptors operates via a Gi 
protein–linked pathway to reduce cAMP synthesis, thus  reduces rate. cAMP is critical to 
pacemaker rate because of its action on the HCN (hyperpolarization activated cyclic 
nucleotide gated) channels that determine its function (Biel et al 2002). Taking in 
consideration, none of the ion currents described is uniquely responsible for pacemaker 
activity. All contribute, and marked alteration in any one can be balanced by altered 
function of the others, such that pacemaker activity persists, albeit at different rates. This 
redundancy in function is important to maintain the initiation and maintenance of the 
heartbeat under a variety of circumstances. A good example is the effect of ivabradine on 
sinoatrial rate: The latter may decrease by as much as 30%, accounting for the therapeutic 
effect of the drug, but effective pacemaker function is preserved (Thollon et al 2007). All 
currents contribute in such a way to permit the generalization that any event that increases 
inward current and/or decreases outward current will increase pacemaker rate. 
5. Transcription factors and conduction system (Table 1) 
Cardiac conduction system components work together as a functional unit to provide the 
rhythmic activity of the heart. Transcription factors, including homeodomain proteins and 
Tbox proteins, are at the core of pathways specifying the components of the cardiac 
conduction system. They are essential in activating or repressing a constellation of 
regulatory genes, most of which still remain unidentified. Together, the transcription factors 
and regulatory genes specify and maintain the cardiac conduction system in a normally 
functioning state. Mutations in genes encoding some of these transcription factors produce 
human disorders defined by the presence of congenital heart defects as well as associated or 
isolated conduction system abnormalities. In addition to the transcription factors that 
specify cell lineages destined to become part of the cardiac conduction system, several 
transcription factors regulate expression of genes encoding the ion channel proteins. Ion 
channels are essential in contributing to the electrophysiological properties of the 
conduction system by maintaining the membrane potential of myocardial cells and 
controlling the release of ions necessary for eliciting a muscle contraction. Dysregulation of 
these ion channels due to alterations in expression of their modulatory transcription factors 
can affect proper functioning of the conduction system and lead to the manifestation of 
arrhythmias. Further characterization of the molecular programs involved in cardiac 
conduction system specification, maintenance and function, and ion channel expression 
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should lead to improved diagnosis and therapy of conduction system disease. (Hatcher et al 
2009). Recent study report that the Shox2 homeodomain transcription factor is restrictedly 
expressed in the sinus venosus region including the SA node and the sinus valves during 
embryonic heart development. Shox2 null mutation results in embryonic lethality due to 
cardiovascular defects, including an abnormal low heart beat rate and severely hypoplastic 
SA node and sinus valves attributed to a significantly decreased level of cell proliferation. 
Genetically, the lack of Tbx3 and Hcn4 expression, along with ectopic activation of Nppa, 
Cx40, and Nkx2-5 in the Shox2−/− SAN region, indicates a failure in SA node differentiation. 
Furthermore, Shox2 overexpression in Xenopus embryos results in extensive repression of 
Nkx2-5 in the developing heart, leading to a reduced cardiac field and aberrant heart 
formation. Reporter gene expression assays provide additional evidence for the repression 
of Nkx2-5 promoter activity by Shox2. (Ramón et al 2009).  
 
Transcription 
Factor 
Expression  in 
Cardiac Conduction 
System 
Role in Cardiac Conduction System 
Development 
Nkx2.5 
AV node, AV bundle, 
BBs, PF 
specification of AV node lineage & peripheral 
conduction system 
Shox2 SA node, BBs SA node specification and gene expression 
Hop 
AV node, His 
bundle, BBs 
maintenance of proper CCS gene expression 
and function 
Irx4/Irx5 
none (ventricular 
myocardium) 
regulation of ventricular ion channel  
expression 
Tbx2 
AV node, AV ring 
bundle 
specification of AV node and AV ring bundle 
Tbx3 
SA node, AV node, 
AV bundle, proximal 
BBs 
SA node induction, compartmentalization & 
maintenance, AV conduction tissue 
specification and patterning, suppression of 
myocardial gene expression in atria and 
ventricles 
Tbx18 SA node SA node compartmentalization 
Tbx5 
AV node, His 
bundle, BBs 
postnatal maturation of AV node, AV bundle & 
left BB; right BB patterning 
Id2 
AV node, AV bundle, 
BBs 
ventricular myocyte conduction system 
specification and function via cooperative 
regulation by Nkx2.5 & Tbx5 
SA; sinoatrial node, AV; atrioventricular bundle, BB; bundle branch, PF; Purkinje fiber 
Table 1. Transcription factors involved in cardiac conduction system specification, 
patterning, maturation & function. (Hatcher et al 2009). 
6. Why biological pacemakers needed 
Although electronic pacemakers reduced mortality associated with complete heart block 
and morbidity of sinoatrial node dysfunction, still they have disadvantages:  
1. The imposed limitations on the exercise tolerance and cardiac rate-response to emotion. 
Despite the use of paradigms to improve heart rate response during increased physical 
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activity, there is no substitute currently available for the autonomic modulation of heart 
rate.  
2. In pediatrics, patient age and size, the mass of the power pack, and the size and length 
of the electrode catheter are important considerations. The hardware must be tailored to 
the growth of the patient.  
3. The placement site of the stimulating electrode in the ventricle and the resultant 
activation pathway may have beneficial or deleterious effects on electrophysiologic or 
contractile function.   
4. The long-but-limited life battery expectancy, requiring testing and replacement at 
periodic intervals.  
5. Infection may require removal and/or replacement of the pacemaker.  
6. Various devices including neural stimulators metal detectors and magnetic resonance 
imaging equipment have been reported to interfere at times with electronic pacemaker 
function. (Furrer et al 2004, Martin et al 2004).  
So a biological alternative that might last for the life of the patient, respond to physiologic 
demands for different heart rates at different times, and activate the heart via a pathway 
tailored to the anatomy of disease in any individual is an exciting possibility. An ideal 
biological pacemaker should; 
1. Create relatively aceepted physiologic rhythm for the life of the individual. 
2. Needs no battery or electrode, and no replacement.   
3. Effectively compete in direct comparison with electronic pacemakers.  
4. Have no inflammatory or infectious potential.  
5. Not carcinogenic. 
6. Adapt to changes in physical activity and/or emotion with appropriate rapid changes 
in heart rate.  
7. Propagate through an optimal pathway of activation to maximize efficiency of 
contraction and cardiac output. 
8. Not arrythmogenic. 
9. Potentially curative. 
7. Strategies for building a biological pacemaker 
Three strategies reported till now to create biological pacemaker activity: 
1. Up-regulation of adrenergic neurohumoral actions on heart rate (Edelberg1998, 2001).  
2. Reduction of repolarizing current (Miake et al 2002). 
3. Increasing inward current during diastole (Qu et al 2003).  
All three strategies had their foundations in 20th century pharmacology and physiology. In 
studies of autonomic modulation, increased heart rate via beta-adrenergic catecholamines or 
sympathetic stimulation through an increase in pacemaker current in the sinus node and in 
accessory pacemakers, whereas increasing vagal tone or stimulating muscarinic receptors 
decreased heart rate (DiFrancesco et al 1986, Campbell et al 1989). In studies of ionic 
determinants of pacemaker activity, augmentation of hyperpolarizing, outward currents 
decreased pacemaker rate (Di Francesco et al 1995), suggesting that the opposite 
intervention, i.e. decreasing hyperpolarizing, outward currents, would increase rate (Miake 
et al 2002). Pharmacological experiments demonstrated that suppressing inward current 
carried by the T-type or L-type Ca channel slows pacemaker rate. (Lasker et al 1997, 
Robinson, Di Francesco 2001). What are needed are the tools to apply this knowledge to the 
molecular and genetic determinants of the pacemaker potential. 
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The necessary information was provided in part via the identification and cloning of the 
gene products that determine the beta adrenergic receptors, the inward rectifier current, and 
the pacemaker current. Also of central importance was the development of tools for; 1- gene 
therapy, wherein genes encoding the molecular subunits of interest are inserted via 
plasmids or viral vectors into cells of the myocardium; 2- cell therapy via the use of 
embryonic stem cells, whose differentiation is directed into myocardial precursors 
manifesting pacemaker activity, or mesenchymal stem cells used as platforms to implant 
channels into cardiac myocytes. A critical factor is the development of models in which to 
test pacemaker constructs. In vitro models of cells in culture are a standard for testing a 
variety of gene therapies it has been found that infecting neonatal rat ventricular myocytes 
with replication-deficient adenoviral constructs incorporating the gene of interest (with or 
without coexpression of GFP) provides a cost-effective and reproducible assay (Qu et al 
2001). Using a variation on this model for testing the ability of stem cells to transmit the 
electrical signal of interest (Potapova et al 2004). It has been  considered that a 100 times or 
more overexpression of current and a statistically significant effect on beating rate as 
standards that discriminate efficacy, More research is required to establish uniform 
guidelines permitting reliable correlation of in vitro and in vivo effectiveness. As an intact 
animal screen, the use of guinea pig (Miake et al 2002), swine (Edelberg et al 2001), and dog 
(Qu et al 2003, Plotnikovet al 2004, Potapova et al 2004) has been reported. The use of dog is 
based on its cardiac size, tractability as a chronic model, and similar electrophysiologic 
properties to those of man. 
8. Vectors and methods of gene delivery 
Gene therapy is defined as the transfer of nucleic acids to somatic cells as therapeutically 
useful molecules. Human genome has approximately 30,000 genes. The genetic diversity is 
amplified by alternate splicing of mRNA and post translational modification of proteins. 
The possible gene targets for arrhythmias are very large. The molecular targets of 
arrhythmia management are the ion channels and the modulators of ion channels like G 
proteins (Members of the Sicilian gambit 2001).  A vector is the vehicle commonly used to 
introduce the gene to the target cell. It may be RNA or DNA viruses or non viral in nature. 
Viruses which have the capacity to incorporate themselves in the host genome are used as 
vectors for gene therapy. The commonly used viral vectors are genetically modified 
retroviruses, adenoviruses, adeno associated viruses and lentiviruses. These viral vectors are 
replication deficient to ensure safety, but require large amounts of vector particles for 
efficacy. Non viral vectors based on plasmids, DNA- lipid complexes and naked DNA are 
also used since they lack foreign proteins and avoid immunological problems. The 
feasibility of gene transfer has been demonstrated in both animals and humans. The extent 
of gene transfer and expression is low in clinical settings compared to experimental 
laboratory. The period during which a newly introduced gene is expressed is often short but 
variable and differs with the tissue. For example, early-generation non-viral vectors express 
the gene at maximum levels only for a few days (Lee et al 1996). Many adenoviral vectors 
express the gene for 2-3 week (Armentano et al 1997). Non viral vectors again have short 
duration of gene expression. This short duration of gene expression  may necessitates repeat 
dosing, although less efficacious. In contrary, expression from adeno-associated viral vectors 
may not peak for several weeks, but then remain constant in some tissues for several months 
(Yla-Herttuala &Martin 2000). Retroviruses produce a long lasting effect by integration of 
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the transfected gene into the host genome (Smith 1999). Various novel methods of 
transfection have been tried in animal models, including DNA polymer coating on inert 
materials and subsequent transfer to the atrial myocardium, with sustained gene activity, 
the classical methods of vector delivery are direct injection into the myocardium, infusion 
through the coronary arteries or administration to the epicardium. (Labhasetwar et al 1998). 
Intracoronary perfusion is another modality of gene transduction with near complete 
expression under optimal conditions (Donahue et al 1997). The gene transfer efficiency 
depends on the coronary flow rate, virus concentration, exposure time and microvascular 
permeability. Agents which increase the microvascular permeability have been used to 
enhance the delivery. Only few generalizations can be made about the vector selection and 
the method of gene delivery, and each disease has its own target tissue and the amount of 
gene product required for treatment. None of the currently available vectors satisfy the 
criteria of an ideal gene therapeutic system. 
9. Global versus local administration 
Permeabilizing agents, vasodilators and vascular endothelial growth factor (VEGF) have 
been used to facilitate gene delivery to large or localized regions of the heart. Cooling and 
aortic cross-clamping have been employed to improve gene delivery through the 
distribution of a coronary artery or the flooding of a chamber or chambers, Not only do 
these approaches appear excessive for clinical application but the best success to date seen in 
about 50% of cells in any region transfected, with viral transfer being diffusion-limited and 
especially problematic in the ventricles. (Lehnart&Donahue 2003, Roth et al 2004). 
Tempering interest in some viral vectors are concerns about inflammation, chronic illness or 
neoplasia. These issues led to exploration of hMSCs as platforms for gene delivery. That 
hMSCs can be loaded with specific gene constructs and delivered to the heart without 
eliciting inflammation or rejection and not differentiating into other cell types. But long-term 
stability of hMSC therapies raises concern about migration to other sites, differentiation into 
other cell types, and duration of expression of genes of interest. The use of various markers 
to trace cell location should facilitate investigators understanding of the extent of hMSC 
localization to sites of administration. (Potapova et al 2004, Rosen 2005, Zimmett et al 2005, 
Plotnikov et al 2007). Cell therapies generally have been intended to regenerate and repair 
myocardium rather than to be specifically antiarrhythmic. While it has been found that 
hMSCs to be adequate delivery platforms for ion channel generated currents, it has been 
followed for 6 weeks only (Plotnikov et al 2007). The question of long-term applicability will 
await long-term studies of hMSC survival as well as comparison with gnomically-
incorporated viral constructs. 
Somatic gene therapy provides a conceptually attractive strategy for modifying the global 
cardiac electrophysiological substrate in disease states such as the inherited and acquired 
long QT syndromes. Another attractive target for local gene therapy may be to selectively 
modify the conduction properties of the AV node. This may be of value in the treatment of 
atrial fibrillation. (Nattel 2002). The feasibility of using gene therapy for AV nodal 
modification in an attempt to control the ventricular rate during atrial fibrillation  
demonstrated by  using adenoviral gene delivery selectively to the AV nodal region via the 
coronary circulation; the AV nodal conduction properties could be modified by 
overexpression of an inhibitory G protein (G alpha i2). G alpha i2 overexpression in the AV 
nodal cells suppressed baseline atrioventricular conduction and slowed the ventricular rate 
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during atrial fibrillation without producing complete heart block, thus mimicking the effects 
of beta-adrenergic antagonists (Donahue 2000). More appealing targets in the short term 
may be arrhythmias in which localized manipulation of the electrophysiological substrate 
may be sufficient to allow effective treatment. 
Recent study, investigated the effect of overexpression of the cardiac potassium channel 
missense mutation Q9EhMiRP1. This gene mutation is one of the known causes of the long 
QT syndrome and results in diminished potassium currents following clarithromycin 
administration. In vitro transfection of the Q9E-hMiRP1gene resulted in a clarithromycin 
induced reduction of the potassium outward current in the transfected cells when compared 
to wild-type hMiRP1 overexpression. With the utilization of a novel gene delivery 
technique, both plasmids were injected locally into the pig’s atrial myocardium with 15% of 
the atrial cells being transfected. This study conclude that overexpression of this mutated 
channel gene may have an inducible localized class III-like antiarrhythmic effect on the 
atrial tissue that may be used in the future for the treatment of reentrant atrial arrhythmias 
(Burton et al 2003). Viral vector-based therapies are not yet applied clinically to arrhythmia 
management but have been effective in proof-of-concept experiments suggesting that gene 
therapy can be of use.  
10. Cell therapy for the treatment of cardiac arrhythmias (Table 2&3) 
An alternative approach to overcome the shortcomings of gene therapy may be the use of 
genetically modified cell grafts that can be initially transfected ex vivo with excellent long-
term efficiency and then transplanted to the in vivo heart. This will require the following:  
1. Establish the proper cell sources for transplantation. 
2. Assessment of the phenotypic structural and functional properties of the cell grafts, in 
vitro.  
3. Establish transplantation strategies to deliver the cells to the desired locations.  
4. Achieve the desired in vivo effect by assuring the survival of the cell grafts, their 
integration and interactions with host tissue, and their proper function. 
Cell therapy can be applied for the treatment of cardiac arrhythmias at three different levels:  
1. Replace absent or malfunctioning cells of the conduction system.  
2. Modify the myocardial electrophysiological substrate by using cell grafts genetically 
engineered to express specific ionic channels, which can couple and modify the 
electrophysiological properties of host tissue through electrotonic interactions.  
3. Modify the myocardial environment by local secretion of specific recombinant proteins.   
A major limitation for the development of such cell replacement strategies is the paucity of cell 
sources for human cardiomyocytes. The use of the recently described human embryonic stem 
cell lines may be solution to this cell-sourcing problem (Gepstein 2002). These unique cell lines 
have the capability to be propagated in vitro in the undifferentiated state in large quantities and 
to be coaxed to differentiate to a plurality of cell lineages, including cardiomyocytes (Kehat et al 
2001a). This differentiating system is not limited to the generation of isolated cardiac cells, but 
rather a functional cardiac syncytium is generated with a stable pacemaker activity and 
electrical propagation (Kehat et al 2002). that can also respond to adrenergic and cholinergic 
stimuli. The ability to generate, ex vivo, different subtypes of human cardiomyocytes (with 
pacemaking-, atrial-, ventricular-, or Purkinje-like phenotypes) (Mummery et al 2003) that could 
lend themselves to genetic manipulation may be of great value for future cell therapy strategies 
aiming to regenerate or to modify the conduction system. 
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The ability of the grafted cells (pacemaker cells or conductive tissue) to integrate structurally 
and functionally with host tissue is a sole requirement. The human ES cell derived 
cardiomyocytes were able to integrate ex vivo both structurally and functionally with 
preexisting cardiac tissue and to generate a single functional syncytium (Kehat et al 2001 b). 
Whereas it is not surprising that cardiomyocyte cell grafts can form intercellular connections 
with host cells (Isner 2002). Recent studies have demonstrated that other cell types such as 
fibroblasts (Rook et al 1992, Fast et al 1996, Gaudesius et al 2003) are also capable of forming 
gap junctions with host cardiomyocytes and that specific electrotonic interactions can be 
generated between these cells. The feasibility of using genetically engineered fibroblasts, 
transfected to express the voltage-gated potassium channel Kv1.3, to modify the 
electrophysiological properties of cardiomyocyte cultures have been examined, in a study, 
using a high-resolution multi-electrode array mapping technique to assess the 
electrophysiological and structural properties of primary neonatal rat ventricular cultures. 
The transfected fibroblasts were demonstrated to significantly alter the electrophysiological 
properties of the cardiomyocyte cultures. These changes were manifested by a significant 
reduction in the local extracellular signal amplitude and by the appearance of multiple local 
conduction blocks (Feld et al 2002). The location of all conduction blocks correlated with the 
spatial distribution of the transfected fibroblasts as assessed by vital staining and all of the 
electrophysiological changes were reversed following the application of a specific Kv1.3 
blocker. 
Genetically engineered cell grafts, transfected to express potassium channels, can couple 
with host cardiomyocytes and alter the local myocardial electrophysiological properties by 
reducing cardiac automaticity and prolonging refractoriness. Investigators studied the ex 
vivo, in vivo, and computer simulation studies to determine the ability of transfected 
fibroblasts to express the voltage-sensitive potassium channel Kv1.3 to modify the local 
myocardial excitable properties. Co-culturing of the transfected fibroblasts with neonatal rat 
ventricular myocyte cultures resulted in a significant reduction (68%) in the spontaneous 
beating frequency of the cultures compared with baseline values and co-cultures seeded 
with naive fibroblasts. In vivo grafting of the transfected fibroblasts in the rat ventricular 
myocardium significantly prolonged the local effective refractory period from an initial 
value of 84 +/-8 ms (cycle length, 200 ms) to 154+/-13 ms (P<0.01). Marga toxin partially 
reversed this effect (effective refractory period, 117 +/-8 ms; P <0.01). In contrast, effective 
refractory period did not change in nontransplanted sites (86+/-7 ms) and was only mildly 
increased in the animals injected with wild-type fibroblasts (73+/-5 to 88+/-4 ms; P<0.05). 
Similar effective refractory period prolongation also was found during slower pacing drives 
(cycle length, 350 to 500 ms) after transplantation of the potassium channels expressing 
fibroblasts (Kv1.3 and Kir2.1) in pigs. (Yankelson et al 2008). 
The possible utilization of cell grafts (fibroblasts, different stem cell derivatives, or other cell 
sources) that can be genetically manipulated ex vivo to display specific electrophysiological 
characteristics and then grafted to the in vivo heart may possess a number of theoretical 
advantages over direct gene therapy. These advantages may be related to a better efficiency 
and control of the transfection process ex vivo, the ability to screen the phenotypic 
properties of the cells before transplantation, and the possible achievement of long-term 
effect because cardiac cell grafts were demonstrated to survive for prolonged periods 
following transplantation (Muller-Ehmsen et al 2002). Yet, determining the optimal way for 
the delivery of the cells, controlling their survival following transplantation, assuring 
appropriate integration of the cells with host tissue, and developing means to control the 
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required electrophysiological effect are all important obstacles for the future use of this 
approach as a therapeutic strategy. 
Ischemic heart disease represents one of the most important conditions predisposing to 
arrhythmias. A variety of preclinical and clinical studies have demonstrated the potential 
utility of gene therapy in the management of chronic ischemic patients through the local 
secretion of angiogenic growth factors such as vascular endothelium growth factor (VEGF) 
and fibroblast growth factor (Isner 2002). Cell therapy strategies may similarly play a dual 
role in promoting angiogenesis. First, cells transfected ex vivo may be used for sustained 
local release of recombinant proteins with angiogenic properties following in vivo grafting. 
Second, transplantation of specific cell types such as endothelial progenitor cells may 
contribute directly to the neovascularization process. The improved understanding of the 
molecular pathways involved in the development of heart failure allow definition of several 
molecular targets for gene therapy to improve systolic and diastolic properties of failing 
myocytes . To focus on modulating calcium homeostasis, manipulating the beta-adrenergic 
receptor signaling pathways, and improving cardiomyocyte resistance to apoptosis need to 
be looked for in future strategies. Similarly, cellular cardiomyoplasty and tissue engineering 
approaches to regenerate functional myocardium also represent a novel approach for the 
treatment of heart failure (Reinlib & Field L 2000, Hajjar et al 2000, Kehat et al 2001 b). 
11. Gene therapy for the treatment of bradyarrhythmias (table 2) 
Implanted pacemakers have become the preferred treatment for sinus node dysfunction and 
high-grade AV block with excellent results with very low morbidity (Kusumoto & 
Goldschlager 1996). Nonetheless, the ideal therapy for these disorders may be the 
development of a biological solution allowing reconstitution of the physiological electrical 
activity of the cardiac conduction system with the same plasticity and adaptability to the 
human body and to the physiology of the cardiovascular system.   Recently; investigators 
hypothesized that overexpression of an engineered HCN construct via somatic gene transfer 
offers a flexible approach for fine-tuning cardiac pacing in vivo. Using various 
electrophysiological and mapping techniques, the authors examined the effects of in situ 
focal expression of HCN1- DeltaDeltaDelta, the S3-S4 linker of which has been shortened to 
favor channel opening, on impulse generation and conduction. Porcine models of sick-sinus 
syndrome by guided radiofrequency ablation of the native SA node were generated 
followed by implantation of a dual-chamber electronic pacemaker to prevent bradycardia-
induced hemodynamic collapse. Interestingly, focal transduction of Ad-CGI-HCN1-
DeltaDeltaDelta in the left atrium of animals with sick-sinus syndrome reproducibly induced 
a stable, catecholamine-responsive in vivo “bioartificial node” that exhibited a physiological 
heart rate and was capable of reliably pacing the myocardium, substantially reducing 
electronic pacing (Tse Hung et al 2006). 
Overexpression of the pacemaker-specific current is an interesting strategy for the 
generation of a biological pacemaker. Investigators assessed the ability of localized 
overexpression of the hyperpolarization-activated, cyclic nucleotide-gated (HCN-2) isoform 
pacemaker current to generate stable pacemaking activity in vivo. Four days after the 
injection of adenoviral constructs of the mouse HCN2 into the canine left atrium, the 
emergence of a new atrial pacemaking activity during vagal stimulation-induced sinus 
arrest were seen. Electrophysiological mapping localized the source of this activity to the 
injection site at the left atrium. Whole cell electrophysiological recordings from transfected 
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myocytes demonstrated the presence of a relatively high-magnitude pacemaker current. (Qu 
et al 2001). 
Enhancement of the chronotropic response of the native pacemaking cells is another 
strategy proposed to regulate the normal pacemaking activity of the heart by local gene 
delivery (Edelberg 1998, 2001). Aiming to enhance the responsiveness of the native atrial 
pace making cells to adrenergic input through up regulation of the Beta 2-adrenergic 
receptors. Using detailed ex vivo and in vivo studies, the authors demonstrate a significant 
positive chronotropic effect following overexpression of the human beta 2-adrenergic 
receptor in atrial tissue. 
The above studies demonstrated the ability of local gene delivery to alter the chronotopic 
properties of the heart; it mainly focused on modifying the function of existing and 
abnormal pacemaking cells rather than actually creating a new biological pacemaker. 
Another strategy for the creation of a biological pacemaker in vivo was described is based 
on the production of dominant negative inhibition of the Kir2-encoded inward rectifier 
potassium channels (Ik1) in ventricular myocytes (Kir2.1AAA). The Ik1 current, which is 
intensely expressed in atrial and ventricular myocytes but not in the pacemaking nodal cells, 
maintains the negative resting membrane potential of ventricular myocytes and thereby, 
suppresses any spontaneous diastolic activity. The investigators hypothesized that 
dominant negative inhibition of this current could restore the latent pacemaking activity in 
these cells and convert the quiescent ventricular myocytes into pacemaking cells. adenoviral 
gene delivery of Kir2.1AAA into the left ventricular cavity of guinea pigs was performed. In 
some of the animals studied, electrocardiogram recordings demonstrated the emergence of a 
new ventricular source of impulse initiation. In vitro electrophysiological recordings from 
the transfected myocytes demonstrated, electrophysiological properties and spontaneous 
activity resembling those of genuine pace making cells. (Kubo et al 1993, Miake et al 2002). 
 
 
Table 2. Possible approach for biological pace maker for treatment of Bradyarrhythmias . 
12. Gene therapy for the treatment of tachyarrhythmias (Table 3) 
Different mechanisms underlying various cardiac tachyarrhythmias (reentry, triggered 
activity, and abnormal automaticity) result from abnormalities in the myocardial 
electrophysiological or structural substrate. That may be anatomic or functional and may be 
localized to a specific area within the myocardium or affect the heart globally. These 
abnormalities may be inherited (different monogenic ion channel mutations in the 
congenital long QT syndrome, Brugada syndrome, etc.) or acquired in a variety of clinical 
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conditions (ischemic heart disease and heart failure leading to ventricular tachyarrhythmias 
or diseased atria leading to atrial fibrillation) (Keating & Sanguinetti 2001, Marban 2002, 
Roberts & Brugada 2003). 
Understanding of the electrophysiological abnormalities leading to the development of the 
different rhythm disorders is needed to target specific genes that will either reverse the 
abnormal phenotype or modify the excitable properties of the myocardial substrate in a 
favorable way. An attractive target for this type of somatic gene therapy may be to correct 
the abnormal global electrophysiological substrate in the inherited or acquired long QT 
syndromes, which can be familial, or inherited (autosomal recessive or dominant trait), or 
acquired in a variety of clinical conditions, is characterized by the prolongation of the QT 
interval in the electrocardiogram and by an increased risk for the development of 
ventricular arrhythmias and sudden cardiac death (Keating & Sanguinetti 2001, Marban 
2002). 
Heart failure represents a prototype of an acquired long QT condition, which predisposes 
the patients to the development of ventricular arrhythmias. Experimental evidence have 
shown that such increased propensity for ventricular arrhythmias may originate partly from 
the downregulation of K+ currents (namely Ito and Ik1) in failing myocytes leading to 
significant prolongation of the action potential duration (APD) (Beuckelmann et al 1993, 
Marban 1999). Action potential duration prolongation in failing myocytes may initially be 
an adaptive response because it increases the time available for excitation-contraction 
coupling thereby augmenting myocardial contractility. But such process may be 
maladaptive, predisposing the ventricle to early afterdepolarizations (EADs), 
inhomogeneous repolarization, and the development of lethal ventricular arrhythmias on 
the long term bases. 
Electrical alternans has been linked to the development of ventricular arrhythmias. 
Increasing the rapid component of the delayed rectifier current (IKr) may suppress electrical 
alternans and may be antiarrhythmic. IKr in isolated canine ventricular myocytes were 
increased by infection with an adenovirus containing the gene for the pore-forming domain 
of IKr [human ether-a-go-go gene (HERG)]. The voltage at which peak IKr occurred were 
significantly less negative in HERG-infected myocytes, thereby shifting the steady-state 
voltage-dependent activation and inactivation curves to less negative potentials (HuaF et al 
2004). This has supported the idea that increasing IKr may be a viable approach to 
suppressing electrical alternans and arrhythmias. 
Recent study has pursued a novel gene transfer approach to modulate electrical conduction 
by reducing gap junctional intercellular communication (GJIC) and hence potentially 
modify the arrhythmia substrate. With ultimate goal of developing a nondestructive 
approach to uncouple zones of slow conduction by focal gene transfer. Lentiviral vectors 
encoding connexin43 (Cx43) internal loop mutants were produced and studied in vitro. 
Transduction of neonatal rat ventricular myocytes (NRVMs) revealed the expected sub-
cellular localization of the mutant gene product. Fluorescent dye transfer studies showed a 
significant reduction of GJIC in NRVMs that had been genetically modified. Additionally, 
adjacent mutant gene-modified NRVMs displayed delayed calcium transients, indicative of 
electrical uncoupling. Multi-site optical mapping of action potential (AP) propagation in 
gene-modified NRVM mono-layers revealed a 3-fold slowing of conduction velocity (CV) 
relative to non transduced NRVMs. In conclusion; lentiviral vector–mediated gene transfer 
of Cx43 mutants reduced GJIC in NRVMs. Electrical charge transfer was also reduced as 
evidenced by delayed calcium transients in adjacent NRVMs and reduced CV in NRVM 
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monolayers. These data validate a molecular tool that opens the prospect for gene transfer 
targeting gap junctions as an approach to modulate cardiac conduction (Eddy et al 2007). 
Because heart failure is characterized by both depressed contractility and delayed 
repolarization, the unopposed correction of the latter by the strategies described above may 
further aggravate the already depressed mechanical properties. In vivo, this dual gene 
therapy approach resulted in abbreviation of the QT interval with preservation of 
contractility this has been shown by a group of investigators designed a novel dual gene 
strategy aiming to offset the loss of contractility due to the potassium current-induced action 
potential duration shortening with the overexpression of the calcium ATPase sarcoplasmic 
reticulum Calcium ATPase (SERCA). Using a bicistronic adenoviral vector allowing a single 
promoter to drive the co expression of two genes, the authors co expressed in guinea pig 
hearts the Kir2.1 cardiac inward rectifier potassium channel together with SERCA1. 
Myocytes isolated from these hearts demonstrated shortened action potential durations 
when compared with controls but also displayed larger calcium transients. (Ennis et al 
2002). The rational for using SERCA in the dual gene therapy strategy, originates from 
previous studies showing the ability of SERCA overexpression to augment cardiac 
contractility by increasing sarcoplasmic reticulum calcium loading (Hajjar et al 2000). 
Overexpression of SERCA alone also resulted in a favorable electrophysiological effect 
manifested by shortening of action potential duration and a significant reduction in the 
incidence of after contractions in the transfected myocytes (Davia et al 2001, Terracciano et 
al 2002). 
 
 
Table 3. Possible approach for biological pace maker for treatment of Tachyarrhythmia. 
13. Ventricular tachycardia & fibrillation 
Whereas myocardial infarct-induced arrhythmias might respond to local therapy, variations 
in anatomy from patient to patient require extensive mapping to determine sites at which to 
localize therapy. Using mapping to identify sites for local radiofrequency ablation reduced 
www.intechopen.com
 
Cardiac Pacemakers – Biological Aspects, Clinical Applications and Possible Complications 
 
16
the need for defibrillation in patients who had devices implanted for secondary prevention. 
Using mapping to identify the border zone of an infarct in a canine model ablation were 
replaced with intramyocardially-administered gene therapy in preliminary studies and 
without destroying tissue - achieved a reduction in VT/VF incidence (Reddy et al 2007, Lau 
et al 2009).  
14. Specific gene therapies for ischemic arrhythmias 
14.1 Speeding conduction via connexins or Na channels 
The importance of connexins and hence gap junctions in arrhythmias has been shown in 
many studies. the overexpression of Cx45 results in ventricular tachycardia in mice 
(Betsuyaku et al 2006) while mutations of Cx40 are associated with atrial fibrillation in 
humans.(Gollob et al 2006) Studies of the epicardial border zone of healing canine 
myocardial infarcts have demonstrated altered connexin distribution and density in regions 
of generation of reentrant ventricular tachycardia.(Peters et al 1997) The modulation of gap 
junctions as an anti-arrhythmic strategy initially attempted to block conduction. However, 
the gap junctional blockers used to date have not been channel specific neither isoform-
specific and in disrupting coupling between cells have been found to cause potentially fatal 
arrhythmias. On the positive side, antiarrhythmic peptides have been used to increase 
junctional conductance. One such peptide, rotigaptide, appears to target Cx43 specifically, 
and may be antiarrhythmic (Dhein et al 2003). 
At least 10 different Na channel genes encode alpha subunits in the mammalian genome; 
these have been cloned from brain, spinal cord, skeletal and cardiac muscle, uterus, and glia 
(Allessie et al 1977). Since slow conduction is an essential feature of reentrant cardiac 
arrhythmias, other mammalian Na channels that might have more favorable properties than 
the cardiac Na channel in circumstances that favor slow conduction were looked for (Lau et 
al 2009). One such circumstance is membrane depolarization, as in myocardial infarction in 
such circumstances  the voltage dependence of steady state Na channel inactivation is of 
interest. The midpoint of the cardiac Na channel (SCN5A) is negative to −73mV. This is 
important because in infarcted tissue when myocytes are depolarized to −65mV virtually all 
SCN5A-derived cardiac Na channels are inactivated. In contrast, skeletal muscle (SkM1) Na 
channels have an inactivation midpoint of −68mV and almost half of these channels would 
be available to open during an action potential in a depolarized cell. This suggests that Na 
channels such as SkM1 with more favorable biophysical properties than SCN5A might be a 
useful antiarrhythmic therapy. The effectiveness of this approach has been shown in a 
canine model in which the incidence of inducible polymorphic VT was 75% of controls and 
17% of SkM1-administered dogs 5 days postinfarction. Moreover, SkM1 administration 
reduced electrogram fragmentation and increased Vmax of phase 0 (consistent with more 
rapid conduction), as had been predicted for SkM1 (Lau et al 2009). 
14.2 Targeting diastolic membrane potential 
In ventricular tachycardia in the setting of a partially healed infarct, the viable but 
depolarized tissue in the border zone provides the substrate for a reentrant arrhythmia 
(Allessie et al 1977). a logical approach to enhance conduction in these circumstances is to 
hyperpolarize diastolic membrane potential, thereby making more Na current available. In 
normal myocytes the diastolic membrane potential is largely set by the inward rectifier IK1 
(generated by Kir2.1 with some contribution from Kir2.2) (Zaritsky 2001). Studies 
overexpressing these channels are needed. 
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14.3 Enhancing rate responsiveness and/or refractoriness 
Reentrant arrhythmias require reexcitation of tissue by a propagating waveform. an 
intervention that facilitates recovery of excitability in the pathway may restore antegrade 
activation and forestall retrograde invasion of that path by the reentering waveform. 
Alternatively, it may speed propagation of the reentering waveform such that it encounters 
tissue that remains refractory. Recent study showed that 6-fold overexpression of native 
hERG eliminates T wave alternans in isolated canine ventricular myocytes and in computer 
simulations (Hua et al 2004). Using a different approach, delivering a dominant negative 
HERG mutant (HERGG628S) via vascular infusion to a peri-infarct zone of pigs. 
Monomorphic ventricular tachycardia (VT) had been consistently inducible in infarcted 
animals before gene transfer, but one week later all HERGG628S- transferred pigs showed 
no such arrhythmia. This result emphasizes the therapeutic potential of yet a different local 
approach to VT therapy in chronic infarcts (Sasano et al 2006). 
15. Long QT syndromes (LQTS) 
Since 1991, 7 LQTS genes have been discovered and more than 300 mutations have been 
identified to account for the disease. Gene therapy has been suggested as a possible way to 
reverse the electrophysiological changes associated with the acquired or congenital long QT 
syndromes. Studies following short-term in vivo transfection in small animals or in isolated 
cultured cardiomyocytes demonstrated that overexpression of the KV4.3 gene encoding the 
Ito can significantly shorten the action potential durations (APD) in myocytes having a 
normal APD at baseline (Johns et al 1995, Hoppe et al 1999, 2000). 
Blockage of the IKr prolongs the QT interval and increases the dispersion of repolarization 
predisposing to torsades de pointes. Molecular genetic analysis could be useful to solve 
subclinical mutations or polymorphisms. Individuals with cardiac potassium channel 
missense mutation, Q9E-hMiRP1 are predisposed to develop QT prolongation after 
clarithromycin administration. Experimental studies have demonstrated that cells 
transfected with plasmid DNA containing Q9E-hMiRP1 have reduced potassium currents 
on exposure to clarithromycin. Site specific gene therapy for arrhythmias by transfecting cell 
clones with the K+ channel genes is a feasible approach to the management of LQTS (Burton 
et al 2003). Mutated K+ channels resulting in loss of function have been implicated in LQT 1 
and 2. The potassium channel alpha subunit genes KCNH2 [HERG] and KCNQ1 [KvLQT1] 
responsible for Ikr and Iks respectively are mutated in LQTS. In normal epithelia, KCNE3 
[E3] interacts with the KVQT1 [Q1] thereby augmenting the potassium currents. E3 subunit 
can be genetically expressed in cardiac tissues, which is normally scarce, to abbreviate the 
action potential duration and enhance the potassium current. This potentially prevents 
arrhythmias in LQTS. Adenovirus encoded E3 introduced into guinea pig ventricles 
shortened QT interval on homogenous transduction, but could be potentially 
arrhythmogenic if transduction is heterogenous (Mazhari et al 2002). Overexpression of a 
foreign potassium channel can also effectively abbreviate the prolonged action potential 
duration (APD) in failing cardiomyocytes. By adenoviral delivery of the inactivated 
defective Drosophila shaker B potassium channel (ShK) to cultured ventricular myocytes 
isolated from the rapid-pacing heart failure canine model resulted in significant shortening 
of the prolonged APDs in these cells. A low level of ShK expression was sufficient to modify 
the action potential waveform of the failing myocytes to resemble that of normal ventricular 
myocytes. However, the importance of adequate control of the level of transgene expression 
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became apparent because higher levels of ShK expression resulted in the generation of 
bizarre-shaped and overly shortened action potentials leading to significant impairment of 
the contractile properties of the transfected myocytes. (Nuss et al 1996). An alternative 
strategy to Ito or Ikr was suggested (Mazhari et al 2002) by over expression of the accessory 
subunit KCNE3 (E3, encoding MiRP2), a well-known positive regulator of the KCNQ1 (Q1, 
encoding KvLQT1) channel in different cell types (Schroeder et al 2000) that is not normally 
expressed in the heart. Ectopic expression of the KCNE3 subunit in ventricular mocytes both 
ex vivo and in vivo lead to its co-assembly with Q1 and to a significant increase in the 
slowly activating delayed rectifier potassium (Iks) current. This in turn resulted in 
significant shortening of APD at the cellular level and of the QT interval when delivered in 
vivo. 
Another candidate current that can be used to shorten the action potential duration is the 
human ether-a-go-go (HERG) encoding the Ikr rapid component of the delayed rectifier 
potassium current. Ikr is believed to play an important role in normal repolarization 
(Trudeau et al 1995). and both naturally occurring mutations as well as pharmacological 
blockade of this current may result in QT prolongation and induction of ventricular 
arrhythmias in predisposed individuals (Keating et al 2001). Adenoviral delivery of the 
HERG gene to cultured rabbit myocytes (which usually develop action potential duration 
prolongation and increased incidence of early afterdepolarizations after a few days in 
culture) resulted in significant action potential duration abbreviation, a significant increase 
in the relative refractory period, and a more than fourfold decrease in the incidence of early 
afterdepolarizations (Nuss et al 1999). 
16. Current problems with gene therapy 
Gene therapy is in stage of infancy. Majority of trials to date are experimental, Except for a 
few human trials. The key to success in gene therapy is primarily dependent on the selection 
of a number of essential elements; an “ideal vector” that can be used to deliver the desired 
transgene to the relevant tissue with goal of transgene expression in the required quantity, 
location, and period to exert its beneficial effects. The choice of the specific vector will 
determine the above properties. It is important to note that only a few vectors, namely 
recombinant adenoviruses, adeno-associated viruses, and perhaps lentiviral vectors can 
achieve efficient, high-level transgene expression in post mitotic cells such as 
cardiomyocytes (Robbins et al 1998). Using the appropriate route of delivery is the next step 
for success. Intracoronary artery catheter delivery, retroinfusion through the coronary veins, 
direct injection into the myocardium using an epicardial or endocardial catheter approach, 
intra-pericardial release, and intra-cavitary catheter delivery during transient cross-
clamping of the aorta were applied till today (Hajjar et al 2000). 
The expected ideal result from gene therapy is a permanent cure of arrhythmias with a 
single stage treatment with minimal or no adverse effects. Clearly we are far from the ideal. 
Problems with vectors include variability in transfection capabilities, inefficient delivery at 
site, limited period of gene expression, and immunogenicity. The level and efficiency of 
expression of many trans genes are suboptimal. The tissue expression of many genes is 
transient. Many viral vectors are potentially immunogenic and carcinogenic.  
Successful transfer of the therapeutic gene to all the myocytes at the target site is not fully 
achieved experimentally. The receptors for many viral vectors are present in many tissues 
thereby limiting the specificity of gene delivery. The interaction between vector and host 
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genome can result in the vector being rendered replicant and lose the therapeutic gene. 
Traditional vectors need to be engineered to increase their affinity for the target tissue or cell 
and prevent transduction to other cells (Baker 2004). In atrial fibrillation gene needs to be 
delivered to a wide area, the transfer methods like direct injection into myocardium fails to 
deliver the gene a short distance from the injection site. Gene therapy for arrhythmia 
treatment may itself being arrhythmogenic. As well as the incomplete restoration. In a non 
linear system like biological organisms, making an isolated change in a specific aberration 
will result in restoration of normal function only if the defect is truly isolated and is the 
direct cause of the phenotypic response. The long term response of a genetic modification in 
the myocardium is unknown, continued research and time is needed to solve these 
problems with certainty. studies described in the previous sections established the feasibility 
of gene delivery to modify the excitable properties of the myocardial tissue but also raise 
several limitations, include those that are inherent to other gene therapy strategies such as 
the possible expression of the transgene in non target organs, the potential to trigger 
autoimmunity, potential toxic effect of the vector or transgene, and host immune response.  
In addition the use of gene therapy for the treatment of cardiac arrhythmias may be 
hampered by a number of specific limitations; 1) limited knowledge of the molecular 
mechanisms underlying many of the cardiac arrhythmias and complexity of ion channel 
expression in various regions of the hearts may preclude the utilization of a single ion 
channel transgene. 2) successful antiarrhythmic gene therapy treatment strategies would 
require, in most cases, sustained long-term expression of the transgene (months or years). 
Such option is not feasible with current vector technologies. 3) limitations is related to the 
inability to adequately control several other key parameters such as the level of transgene 
expression within the cells, the number of transfected myocytes, their transmural 
distribution, and their regional distribution within the heart. In vivo myocardial expression 
using currently available viral vectors is not predictable, is relatively short-lived, is 
inhomogeneous, may lead to increased dispersion of different electrophysiological 
properties, and may actually facilitate the generation of arrhythmias.  
17. Future prospective 
Improvement in the understanding of the mechanisms underlying many of cardiac 
arrhythmias and the development of molecular and cellular tools suggest a future role for 
gene and cell therapies for treatment of different cardiac arrhythmia. Bridging the gap 
between the proof-of-concept and the clinical application will require important 
methodological developments as well as extensive animal experiments. Newer refinements 
in vector development and design are needed to have better transduction in cardiovascular 
tissue. Cell specific regulatory elements and promoters to selectively target the cardiac tissue 
is a potential area of interest (Beck et al 2004). Bacterial gene delivery as an alternative to 
viral vectors has been proposed (Palffy et al 2006). Hybrid vectors, gutted vectors and new 
generation non viral vectors may hold the key to future. Evidence from both viral and stem 
cell approaches state that proof of concept is there. Trials can be designed that permit us to 
test biological versus electronic pacemakers in relative safety in patients who are protected 
from failure of the biological unit. Tandem pacing is the proposed  way to proceed clinically 
(patients with chronic atrial fibrillation and complete heart block); i.e. implant both a 
biological pacemaker and an electronic demand pacemaker in the same individual , this has 
been tested in dogs in complete heart block an adenoviral HCN2 construct (into the left 
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bundle-branch system) were delivered and an electronic demand unit, the electrode of 
which was placed in the right ventricular endocardial apex (Bucchi et al 2006). The 
biological pacemaker fired 70% of the time and was catecholamine responsive. Moreover, 
when the biological unit slowed, the electronic unit took over; similarly, the electronic unit 
sensed the biological unit well and discontinued its function when the biological function 
emerged, the memory function of the electronic unit can track the function of the biological 
unit, providing a record for the cardiologist. 
Given the imperfections that still reside with electronics, the possibility of a system with no 
wires, no hardware, and a software that is of the body’s own ion channels and autonomic 
nervous system offers something more appealing, if it can be made to function at the level 
needed and for the time required. As mentioned above, rate responsiveness is here, and 
improved and leadless systems have arrived as well. Therefore, there are two competitive 
approaches evolving. Which will dominate, traditional electronics upgraded to achieve still 
newer levels of success or biologics, is unknown, and the future will answer. 
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